Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ikeoka, DT; Vieira, CZ; Lemos, PA; Strabelli, TV; da Silva, EER; Perin, MA; Groselj-Strele, A; Tiran, B; Tiran, A; Caramelli, B.
Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting.
CLIN RES CARDIOL. 2009; 98(1): 44-51.
Doi: 10.1007/s00392-008-0722-1
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Ikeoka Dimas
- Co-Autor*innen der Med Uni Graz
- Groselj-Strele Andrea
- Tiran Andreas
- Tiran Beate
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Stent implantation produces a systemic increase of inflammatory markers that correlates with Chlamydophila pneumoniae infection in atherosclerotic plaque. We performed a clinical intervention study to investigate the effect of antibiotic treatment on 6-month follow-up angiographic minimal luminal diameter after stenting. Ninety patients were randomly assigned to oral azithromycin or placebo in a double-blinded and randomized fashion. Medication was initiated 2 weeks before a pre-scheduled stenting procedure and maintained 12 weeks thereafter. Angiographic outcomes were evaluated by a six-month follow-up angiography and laboratorial parameters were accessed by blood sampling 2 weeks before stenting, within the first 24 h after procedure and additional samples after four weeks and 6 months. Minimal luminal diameter (1.76 +/- A 0.56 mm Vs. 1.70 +/- A 0.86 mm; P = 0.7), restenosis rate, diameter stenosis, late loss, and binary restenosis rates were comparable in placebo and azithromycin group in the 6 months follow-up. Serum levels of C-reactive protein presented a three fold significant increase in the control group one day after stenting but did not change in the azithromycin group (8.5 [3.0;16.4] Vs. 2.9 [1.7;6.6]-median [25;75 percentile] P < 0.01). Azithromycin does not improve late angiographic outcomes but attenuates the elevation of C-reactive protein levels after stenting, indicating an anti-inflammatory effect.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Aged -
- Anti-Bacterial Agents - therapeutic use
- Azithromycin - therapeutic use
- C-Reactive Protein - drug effects
- Cell Proliferation - drug effects
- Chlamydophila Infections - etiology
- Chlamydophila pneumoniae - isolation and purification
- Coronary Angiography -
- Coronary Restenosis - etiology
- Double-Blind Method -
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Stents - adverse effects
- Treatment Outcome -
- Tunica Intima - drug effects
- Find related publications in this database (Keywords)
- coronary restenosis
- inflammation
- stents
- randomized controlled clinical trials
- Chlamydophila pneumoniae
- azithromycin